Host: The Japanese Society of Toxicology
Intestinal toxicities/adverse effects have been frequently reported in non-clinical and clinical studies during drug development. Intestinal toxicities themselves are often not life-threatening, but they can significantly reduce the quality of life for patients and may lead them to give up medications. Meanwhile, there are few well-established intestinal injury biomarkers like there are for kidney or liver, making it difficult to monitor intestinal toxicities in non-clinical in vivo research and to translate any findings into clinical contexts.
In this presentation, I will introduce multiple intestinal injury biomarkers, including those at discovery stage. Additionally, I will describe our investigation of these biomarkers in intestinal injury model rats. Finally, the significance of these novel biomarkers to the evaluation of toxicity will also be discussed.
